EXTENDED REPORT

Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis

Cécile Gaujoux-Viala,1 Jackie Nam,2,3 Sofia Ramiro,4,5 Robert Landewé,6 Maya H Buch,2,3 Josef S Smolen,7,8 Laure Gossec9

ABSTRACT

Objectives To update a previous systematic review assessing the efficacy of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in rheumatoid arthritis (RA).

Methods Two systematic reviews of the literature using PubMed, Embase and the Cochrane library were performed from 2009 until January 2013 to assess the efficacy of csDMARDs (as monotherapy or combination therapy) in adults with RA, and the efficacy of glucocorticoids in early RA. A third systematic review was performed until March 2013 to assess the efficacy of tofacitinib by meta-analysis.

Results For glucocorticoids, of 222 hits, five publications relating to four new trials were analysed for efficacy, confirming that initial treatment of RA with low-dose prednisone plus methotrexate (MTX) results in better clinical and structural outcomes at 1 and 2 years than treatment with MTX alone. For csDMARDs, of 498 studies, only two new studies were randomised controlled trials comparing MTX monotherapy with MTX in combination with another csDMARD without differences in glucocorticoid usage. Using tight control principles, clinical outcomes were no better with immediate triple therapy than with ‘step-up’ therapy. For tofacitinib, the pooled analysis of 10 trials showed that tofacitinib was more efficacious on signs and symptoms, disability and appeared to be more efficacious on structural damage than control treatment with placebo (OR 95% CI)—American College of Rheumatology 20% (ACR20) response: 2.44 (1.97 to 3.02) or treatment with MTX (ACR20 response: 2.38 (1.66 to 3.43)).

Conclusions Addition of low-dose glucocorticoids to csDMARD therapy produces benefits in early RA. Under tight control conditions, combination therapy with csDMARDs is no better than MTX monotherapy. Tofacitinib is a new DMARD with proven efficacy.

INTRODUCTION

Since rheumatoid arthritis (RA) imposes a considerable burden for patients, their families and society, therapeutic approaches call for early intervention with, and timely adaptation of, disease-modifying antirheumatic drugs (DMARDs), either as monotherapy or as combination therapy, in order to avoid irreversible damage, long-term disability and premature death. In 2010 a European League Against Rheumatism (EULAR) task force aggregated the available information on RA treatment into practical recommendations,1 based on several systematic literature reviews (SLRs) providing the state of evidence at that time.2–4 DMARDs form two major classes: synthetic chemical compounds (synthetic DMARDs, sDMARDs) and biological agents (bDMARDs). We have now updated these 2009 searches to obtain the available published information on efficacy of synthetic DMARDs as monotherapy or combination therapy, with and without addition of glucocorticoids (GCs). Where appropriate, we will adhere to the recently proposed nomenclature for sDMARDs which, among other aspects, differentiates between conventional synthetic (cs) and targeted synthetic (ts) DMARDs.5

METHODS

The four main research questions pertained to the efficacy on signs and symptoms, disability and joint damage. Topics considered were (1) the addition of GCs to csDMARDs in early RA; (2) methotrexate (MTX) as monotherapy versus its combination with other csDMARDs (disregarding the addition of biological agents discussed elsewhere)6; (3) individual csDMARDs and (4) tofacitinib, a new tsDMARD specifically targeted at inhibition of Janus kinases. Safety concerns were examined in a separate SLR.7 Tapering strategies for GCs were not dealt with in this SLR.

Guidelines for SLRs were followed and are detailed in the online supplementary material.

Study selection

A SLR was performed in PubMed Medline, Embase, Cochrane library and major congress abstracts after January 2009 until January 2013 for GCs and csDMARDs and until March 2013 for tofacitinib. In addition, abstracts of the American College of Rheumatology (ACR) meetings 2011–2012 and EULAR Congresses 2011–2013 were screened and full publications related to such abstracts taken into account until mid-2013. Only randomised controlled trials (RCTs) were included...
in this analysis. The risk of bias of the included studies was assessed using the Cochrane Collaboration's tool for risk of bias.8

Data collection
Efficacy was assessed by the change in signs and symptoms and disability status between baseline and week 24, week 52 and week 104, when available, and by the change in radiographic joint damage between baseline and week 52 and week 104.

Statistical analysis
In each trial the effect size or the standardised response mean for continuous measures and ORs for dichotomous measures were determined to assess the magnitude of the treatment effect. Where possible, pooled effect size, pooled standardised response mean and pooled OR were calculated by meta-analysis, using the inverse of variance method. RevMan V.5.2 (Review Manager, Copenhagen, The Nordic Cochrane Centre, The Cochrane Collaboration, 2012) statistical software was used. Statistical heterogeneity was tested by Q test and I² test. All meta-analyses were carried out using random-effects models in cases of statistical heterogeneity.

RESULTS
Glucocorticoids in early RA
Of 222 potentially relevant articles, five new studies relating to four RCTs were included (table 1). The selection of articles is shown in online supplementary figure A. Of the five studies, two trials were open-label trials with a high ‘risk of bias’ score10; one study was reported only as an abstract at the 2011 EULAR congress10 and two studies were RCTs with a low ‘risk of bias’.9 13 The SAVE (Stop Arthritis Very Early) trial has a particular design since its objective was to prevent development of RA in patients with very early arthritis who did not yet meet RA classification criteria; it did not show efficacy of a single GC injection in this respect, irrespective of added csDMARDs.9 In the other studies all patients had early RA with a mean disease duration of <1 year and a mean Disease Activity Score in 28 joints (DAS28) of between 5.0 and 5.9. Overall, initial treatment of RA with low-dose prednisone plus MTX showed higher rates of remission at 12 and 52 weeks, lower DAS at 24 weeks and lower Health Assessment Questionnaire (HAQ) scores at 24, 52 and 104 weeks (table 1).10–13 A highly informative study (CAMERA II (Computer Assisted Management in Early Rheumatoid Arthritis trial-II)) reported the efficacy of GCs in a 2-year, prospective, randomised, placebo-controlled, double-blind, multicentre trial in 236 patients with early RA (duration <1 year). The MTX plus prednisone (10 mg/day) strategy was more effective than MTX plus placebo in reducing the progression of erosive joint damage at 104 weeks (primary outcome) (table 1). Patients receiving MTX plus prednisone attained sustained remission at an earlier time point during the trial than patients receiving MTX alone. In addition, the need for additional treatment (subcutaneous MTX, ciclosporin or adalimumab) was significantly lower in the MTX plus prednisone group than in the MTX monotherapy group.11

Overall, there were no new safety concerns over 2 years beyond those previously reported.13–15

csDMARDs
Initially, 498 potentially relevant articles were screened by their abstracts.

Efficacy of MTX in monotherapy versus in combination
Two new studies were RCTs comparing MTX monotherapy with MTX in combination with another csDMARD, without differences in GC usage between the arms, in adult RA (selection process shown in online supplementary figure B).

The tREACH study was a randomised, single-blinded clinical trial in patients with recent-onset arthritis who had a ‘high probability of progressing to persistent arthritis’, with three arms: (A) combination therapy with csDMARDs (MTX+sulfasalazine (SSZ)+hydroxychloroquine (HQ)) with intramuscular GCs (91 patients); (B) combination therapy with oral GCs starting at 15 mg/day and tapering over 10 weeks (93 patients) and (C) MTX with oral GCs (same tapering scheme, 93 patients). Medication was intensified to MTX+etanercept (50 mg/week) if the DAS44 was ≥2.4 at 3 months,16 which is rather early in

### Table 1 Randomised controlled trials of glucocorticoids added to DMARDs in early arthritis

<table>
<thead>
<tr>
<th>Study</th>
<th>N</th>
<th>Glucocorticoid regimen</th>
<th>Trial duration (years)</th>
<th>Outcome</th>
<th>Results in glucocorticoids group (%)</th>
<th>Results in control group (%)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Machold, 2010</td>
<td>383</td>
<td>Single IM 120 mg methylprednisolone</td>
<td>1</td>
<td>Drug-free persistent clinical remission (both at 12 and 52 weeks)</td>
<td>16.2</td>
<td>17.8</td>
<td>0.685</td>
</tr>
<tr>
<td>Fedorenko, 2011</td>
<td>141</td>
<td>Prednisolone 10 mg/day or Prednisolone 10 mg/day + methylprednisolone 1 g IV first day</td>
<td>1</td>
<td>‘Clinical EULAR remission’ at 12 weeks* 28.6 (oral GC+IV GC)</td>
<td>21.3</td>
<td>3.1</td>
<td>0.027</td>
</tr>
<tr>
<td>Montecucco, 2012</td>
<td>220</td>
<td>Prednisone 12.5 mg/day to 6.25 mg/day for 2 weeks tapered to 6.25 mg/day for the follow-up period†</td>
<td>1</td>
<td>‘Clinical EULAR remission’ at 52 weeks* 37.5 (oral GC)</td>
<td>29.4 (oral GC+IV GC)</td>
<td>11.4</td>
<td>0.012</td>
</tr>
<tr>
<td>Bakker, 2012†</td>
<td>236</td>
<td>Prednisone 10 mg/day†</td>
<td>2</td>
<td>DAS28≤3.2 at 52 weeks</td>
<td>80.2</td>
<td>75.5</td>
<td>0.44</td>
</tr>
</tbody>
</table>

Studies of glucocorticoids added to MTX except for the study of Machold et al concerning glucocorticoids added to no other therapy, NSAIDs or DMARDs at the investigators’ discretion.

*Study only reported as an abstract at the 2011 EULAR congress: definition of ‘Clinical EULAR remission’ unclear.
†Tight control, treatment to target.
‡DAS28, Disease Activity Score in 28 joints; DMARDs, disease-modifying antirheumatic drugs; GC, glucocorticoids; IM, intramuscular; IV, intravenous; MTX, methotrexate; NSAIDs, non-steroidal anti-inflammatory drugs; SHS, median Sharp–van der Heijde score (interquartile range).
light of the time to maximal effects of csDMARDs and current recommendations. At 3 months (interim analysis) the change in DAS was similar in both arms with the triple combination and higher than in the arm with monotherapy (mean (SD) change: −1.4 (1.0), −1.5 (1.0) and −1.2 (1.0), respectively), but baseline scores for HAQ disability index, tender joint count and C-reactive protein were 10% higher in the monotherapy arm than in both combination arms. Other outcomes, such as change in HAQ score, swollen joint count and erythrocyte sedimentation rate (ESR), did not differ across the groups, and the significant advantage of change in DAS score at 3 months was lost at 1 year.

The Treatment of Early Aggressive Rheumatoid Arthritis (TEAR) study is a 2-year, randomised, double-blind trial with a two-by-two factorial design, of which two arms are pertinent for the current SLR: immediate oral triple therapy (MTX+SSZ+HQ) (132 patients), or step-up from MTX monotherapy to MTX+SSZ+HQ (124 patients) at week 24 if the DAS28-ESR >3.2.18 The objective was to assess which approach is better—that is, to immediately treat all patients with early RA and a more severe phenotype (anti-cyclic citrullinated peptide antibody and/or rheumatoid factor positivity, or erosive disease) with combinations of DMARDs, or to reserve combination DMARD therapy for patients who do not have an appropriate response to monotherapy. The number of participants who did not complete this study was higher (32%) than the authors had originally expected (10%), resulting in loss of statistical power and interpretational problems. Furthermore, the main analysis presented was a completers-only analysis. An earlier improvement occurred with immediate combination arms, but after initial MTX monotherapy in those patients who lacked sufficient response a rapid improvement to similar levels as with immediate triple therapy was seen upon intensification of treatment. There were no radiographic advantages in favour of combination therapy. So, using principles of tight control and treat-to-target, clinical and radiographic benefits were no higher with immediate triple therapy than with ‘step-up’ therapy.18

Efficacy of csDMARDs

Twenty-five studies were analysed. No new data conflicting with the previous conclusions were found. Seven RCTs confirmed the efficacy of MTX as both first and second DMARD.19–24 Only one RCT included leflunomide: it compared MTX and leflunomide in 368 patients with early RA. Of the 240 subjects who were randomised and treated, 129 received leflunomide and 111 received MTX. This study showed that MTX was better than leflunomide for the four primary clinical efficacy endpoints (tender joint count, swollen joint count, physician and patient global assessment score). The difference was not statistically significant for the three secondary clinical efficacy endpoints (morning stiffness, pain intensity, HAQ).25 Very few studies confirmed the efficacy of sulfasalazine.26 27 The studies analysed did not provide new information on other csDMARDs.

Tofacitinib

Literature search results and trials characteristics

Initially, 27 potentially relevant articles were screened. Finally, 10 RCTs were included—four phase II studies and six phase III trials (selection process is shown in online supplementary figure C). Studies’ and patients’ characteristics are detailed in table 2.

Efficacy of tofacitinib at 5 mg twice daily

The meta-analysis showed that tofacitinib was better than the respective control groups in its effect on signs and symptoms and physical function at 12, 24 and 52 weeks. As an example, the pooled OR (95% CI) for ACR20 response at 24 weeks versus placebo was 2.44 (1.97 to 3.02) (figure 1 and online supplementary material).

Radiographic progression was assessed in two studies. In the ORAL Start study (early RA, MTX-naïve) mean change in total Sharp–van der Heijde score (SHS) score at 6 months was 0.18 for tofacitinib 5 mg twice daily versus 0.84 for MTX monotherapy (p<0.05) and the proportion of ‘non-progressors’ (≤0.5 unit increase from baseline in total SHS) was 83.5% versus 70.5%, respectively.27 In the ORAL Scan study (established RA, MTX-inadequate responder), mean change in total SHS score was 0.12 versus 0.47 (p=0.079) at 24 weeks and 0.3 versus 1.0 (p=0.0558) at 52 weeks and the proportion of ‘non-progressors’ was 86% versus 74.1% (p≤0.05) at 52 weeks.28

More details are shown in the online supplementary material.

Table 2 Randomised controlled trials of tofacitinib in rheumatoid arthritis

<table>
<thead>
<tr>
<th>Study</th>
<th>N</th>
<th>Population</th>
<th>Disease duration (years)</th>
<th>Background treatment</th>
<th>Comparator</th>
<th>Trial duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kremer, 2009</td>
<td>264</td>
<td>DMARD-IR</td>
<td>9.5</td>
<td>DMARDs</td>
<td>Placebo</td>
<td>6 Weeks</td>
</tr>
<tr>
<td>Tanaka, 2011</td>
<td>140</td>
<td>MTX-IR</td>
<td>8.3</td>
<td>MTX</td>
<td>Placebo</td>
<td>12 Weeks</td>
</tr>
<tr>
<td>Kremer, 2012</td>
<td>507</td>
<td>MTX-IR</td>
<td>9.5</td>
<td>MTX</td>
<td>Placebo</td>
<td>24 Weeks</td>
</tr>
<tr>
<td>Fleischmann, 2012</td>
<td>384</td>
<td>DMARD-IR</td>
<td>9.0</td>
<td>None</td>
<td>Placebo</td>
<td>24 Weeks</td>
</tr>
<tr>
<td>ORAL Scan</td>
<td>797</td>
<td>MTX-IR</td>
<td>9.0</td>
<td>MTX</td>
<td>Placebo</td>
<td>24 Months</td>
</tr>
<tr>
<td>ORAL Sync Kremer, 2011</td>
<td>792</td>
<td>DMARDs-IR</td>
<td>9.1</td>
<td>Non biological DMARDs</td>
<td>Placebo</td>
<td>12 Months</td>
</tr>
<tr>
<td>ORAL Standard</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Van Vollenhoven, 2012</td>
<td>717</td>
<td>MTX-IR</td>
<td>7.5</td>
<td>MTX</td>
<td>Placebo</td>
<td>12 Months</td>
</tr>
<tr>
<td>ORAL Step* Burmester, 2013</td>
<td>399</td>
<td>TNFi-IR</td>
<td>12.0</td>
<td>MTX</td>
<td>Placebo</td>
<td>6 Months</td>
</tr>
<tr>
<td>ORAL Solo* Fleischmann, 2012</td>
<td>611</td>
<td>DMARDs-IR</td>
<td>8.2</td>
<td>None</td>
<td>Placebo</td>
<td>6 Months</td>
</tr>
<tr>
<td>ORAL Start* Lee, 2012</td>
<td>952</td>
<td>MTX naïve</td>
<td>NA</td>
<td>None</td>
<td>MTX</td>
<td>24 Months</td>
</tr>
</tbody>
</table>

*All trials were randomised controlled trials with a low ‘risk of bias’ score.
**DMARDs, disease-modifying antirheumatic drugs; IR, inadequate responder; MTX, methotrexate; NA, not available; TNFi, tumour necrosis factor inhibitor.
DISCUSSION

This SLR was performed to inform the EULAR task force involved in updating the 2010 recommendations for the management of RA on the efficacy of csDMARDs as monotherapy or combination therapy, with and without GCs in adult patients with RA. Overall, this SLR confirmed the SLRs performed in 2009–2011 and expanded the overall insights.

Although the place of GC therapy in early RA is still a matter of debate, previous studies have clearly shown the benefit of adding GCs to csDMARD monotherapy or combination therapy, whether at low (≤10 mg/day) or higher doses, especially in patients with early RA.38–41 In 2010, we suggested that GCs might be used as ‘bridge therapy’ before slow-acting DMARDs have taken full effect. Several new studies have confirmed these data. Interestingly, the tREACH trial showed that intramuscular and oral GCs are equally effective as bridging treatments16 and thus answered one of the research questions posed in 2010.3 Moreover, accumulating evidence suggests that low-dose treatment is well tolerated and similarly effective, while reducing the risk of side effects associated with higher doses.13 42 However, bone loss should be prevented using appropriate strategies.43 Further research is needed, especially into chronotherapy44 and intra-articular GC therapy.

For combination therapy of csDMARDs, some studies suggest that triple therapy with MTX+SSZ+HQ may be better than MTX monotherapy in improving signs and symptoms.45 46 The tREACH study in its interim analysis at 3 months showed a somewhat faster improvement on DAS28 (but not on HAQ score, swollen joint count or ESR) with triple therapy+GCs than with MTX+GCs, but this difference was not maintained at 1 year.16 17

Moreover the TEAR trial has shown that, using tight control and principles of treat-to-target, clinical, functional and structural outcomes were no better with immediate triple therapy than with ‘step-up’ therapy.18

It has been difficult to interpret the results of several investigator-initiated pragmatic or effectiveness trials such as TEAR and tREACH and use them to choose the most appropriate treatment strategy. These trials are justified by clear practical clinical questions that go beyond whether a particular treatment is effective or not; however, the trial methodology is often so complicated that the trial performance and reporting may be jeopardised. Examples of these aspects are trials that do not reach their target number of patients (with lack of statistical power as a consequence), trials with high drop-out rates, or with relatively small numbers of patients (‘completers’) in which the primary endpoint has been assessed (with a risk of ‘bias by completion’), trials with an unplanned interim analysis or a change of primary endpoint (with the risk of convenience reporting, or reporting at odds with the definite results) and trials with an a priori superiority design that are reported with spurious non-inferiority conclusions.47 However, these studies explored valuable concepts that are of significant practical importance to rheumatologists and patients.

There are some limitations to our analyses; some outcomes from some studies could not be included in this meta-analysis because we needed at least one measure of variability such as SD. Nevertheless, the current SLR informs the Task Force on the evidence that (i) addition of low-dose GC to csDMARD monotherapy or combination therapy increases overall efficacy; (ii) combination of csDMARDs as triple therapy, is efficacious, but MTX monotherapy appears to be similarly efficacious, especially when combined with GCs and employing a treat-to-target approach; (iii) tofacitinib is a clinically, structurally and functionally efficacious agent.

Importantly, safety aspects were not covered here, since they were part of a separate SLR.7

Figure 1  Efficacy of tofacitinib on ACR20 response criteria at 24 weeks.

Author affiliations
1Department of Rheumatology, Nîmes University Hospital; EA 2415, Montpellier I University, Nîmes, France
2Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, UK
3NHRI Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK
4Department of Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
5Department of Rheumatology, Hospital Garcia de Orta, Almada, Portugal
6Department of Clinical Immunology & Rheumatology, Academic Medical Center/University of Amsterdam & Atrium Medical Center, Heerlen, The Netherlands
7Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria
82nd Department of Medicine, Hietzing Hospital Vienna, Vienna, Austria
9Department of Rheumatology, UPMC Univ Paris 06, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Paris, France
Clinical and epidemiological research

Acknowledgements The authors thank Michel Viala for his help with the literature search.

Contributors All authors contributed and finally approved the current manuscript.

Competing interests CG—V: consultation and/or speaking engagements: Abbvie, BMS, MSD, Pfizer, Roche-Chugai, UCB; research funding: Expanscience, Nordic Pharma, Pfizer. JN—consultation and/or speaking engagements: UCB. SR—consultation and/or speaking engagements: Fundação para a Ciência e Tecnologia. RL—consultation and/or speaking engagements: Abbott/AbbVie, Ablynx, Amgen, Astra-Zeneca, Bristol Myers-Squibb, Centocor, Glaxo-Smith-Kline, Merck, Novartis, Pfizer, Roche, Schering-Plough, UCB, Wyeth; research funding: Abbott, Amgen, Centocor, Novartis, Pfizer, Roche, Schering-Plough, UCB, Wyeth. MHB—consultation and/or speaking engagements: Abbott, Bristol Myers-Squibb, Chugai, Pfizer, Roche; research funding: Pfizer. JSS—consultation and/or speaking engagements: Abbott/AbbVie, Amgen, Astra-Zeneca, BMS, Celgene, Glaxo, Infinity, Janssen, Lilly, Medimmune, Menarini, MSD, Novo-Nordisk, Pfizer, Roche, Samsung, Sandoz, Sanofi-Aventis, UCB, Vertex; research funding: Abbott, BMS, MSD, Pfizer, Roche, UCB. LG—consultation and/or speaking engagements: Abbott, BMS, Chugai, Pfizer, Roche, UCB.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

REFERENCES

43 van der Goes MC, Jacobs JW, Jurgens MS, et al. Are changes in bone mineral density different between groups of early rheumatoid arthritis patients treated according to tight control strategy with or without prednisone if osteoporosis prophylaxis is applied? Osteoporos Int 2013;24:1429–36.
Methods

Study selection

1) Glucocorticoids in early RA

A systematic literature search was performed in PUBMED Medline, EMBASE and Cochrane library databases after January 2009 until January 2013, using the followings key-words for articles in English: rheumatoid arthritis, Glucocorticoids, Prednisone, Prednisolone. The trials were initially selected on the basis of their titles and abstract, then on the full texts. Two investigators selected the articles. The inclusion criteria were RCTs reporting the efficacy on signs and symptoms, disability and/or structure of csDMARDs to the same synthetic csDMARD but with different glucocorticoids dose regimen, in adults with early RA (<2 years of duration). Additional studies were identified by hand searching reference lists and abstracts presented at the American College of Rheumatology 2011-2012 and European League Against Rheumatism from 2011 to 2013.

2) csDMARD

Literature published after January 2009 on the following csDMARDs, given in monotherapy and in combination, was examined: methotrexate, leflunomide, sulfasalazine, hydroxychloroquine, intramuscular gold, auranofin, azathioprine, cyclosporine, minocycline, D-penicillamin, cyclophosphamide, chlorambucil, mycophenolate, tacrolimus. Systematic literature search was performed in PUBMED Medline, EMBASE and Cochrane library databases after January 2009 until January 2013, using the following key-words for articles in English: rheumatoid arthritis, name of drug or combination. Additional studies were identified by hand searching reference lists and abstracts presented at the American College of Rheumatology 2011-2012 and European League Against Rheumatism from 2011 to 2013. Concerning the efficacy of MTX in monotherapy versus in combination, we included RCTs
comparing in adult RA, MTX monotherapy to MTX in combination with another csDMARD without glucocorticoid differences.

3) Tofacitinib

A systematic literature search was performed in PUBMED Medline, EMBASE and Cochrane library databases until March 2013 without limitation of year of publication or journal, using the followings key-words for articles in English: rheumatoid arthritis, tofacitinib, Jak inhibitor, CP-690,550. Additional studies were identified by hand searching reference lists and abstracts presented at the American College of Rheumatology 2011-2012 and European League Against Rheumatism from 2011 to 2013. The trials were initially selected on the basis of their titles and abstract, then on the full texts. Two investigators selected the articles. The inclusion criteria were all RCTs reporting the efficacy on signs and symptoms, disability and/or structure of tofacitinib in adult with RA.

Data Collection

Efficacy was assessed by the change in signs and symptoms or disability status between baseline and week 24, week 52 and week 104 when available, and by the change in radiographic joint damage between baseline and week 52 and week 104 when available in both groups.

Two investigators collected the data, using a predetermined form. The following methodological features were collected: blinding, intent-to-treat-analysis or not, number of participants who completed the follow-up. The evaluation of the validity of the included studies was done using the Cochrane Collaboration’s tool for assessing risk of bias.

For each trial, demographic characteristics (sex, mean age), RA duration, background treatment, type of glucocorticoids (with doses), type of DMARD (with doses), type of comparator, and duration of follow-up were collected. Signs and symptoms were extracted.
from the studies, as available, by swollen joint count (SJC), Disease Activity Score (DAS/DAS28), ACR 20, 50, 70 response rates, remission rates, pain, patient global assessment, physician global assessment, erythrocyte sedimentation rate (ESR), C reactive protein; disability was extracted, as available, by the health assessment questionnaire (HAQ or MHAQ); structure was assessed by different scores according to different studies (total Sharp score, Sharp modified by Van der Heijde, Larsen score...).

**Statistical analysis**

In each trial the ES or the SRM for continuous measures and Odds-Ratios (OR) for dichotomous measures were determined to assess the magnitude of treatment effect. The effect size (ES) is calculated as the ratio of the treatment effect (mean differences in treatment group minus differences in control group) to the pooled baseline standard deviation. This calculation entails the use of means, for both baseline and final data with a measure of variability such as SD. The standardized response mean (SRM) is also calculated as the ratio of the treatment effect (mean change in treatment group minus mean change in control group) divided by pooled SD of the change when available. Improvement, e.g. lower pain VAS was considered as a positive change. Every effort was made to calculate the ES or the SRM in all studies. However, if no measure of variability was given the ES or the SRM could not be extrapolated. By convention, an ES <0.2 is usually considered as trivial; 0.2-0.5 as small; 0.5-0.8 as moderate; 0.8-1.2 as important and >1.2 as very important. A SRM >0.8 is considered as large.

Pooled ES, pooled SRM and pooled OR were calculated by meta-analysis, using the inverse of variance method. RevMan version 5.2 (Review Manager, Copenhagen, The Nordic Cochrane centre, The Cochrane Collaboration, 2012) statistical software was used. Statistical heterogeneity was tested by Q test and $I^2$ test. All meta-analyses were carried out with use of random-effects model in case of significant heterogeneity.
Figure A: Literature search strategy for all RCTs reporting the efficacy of glucocorticoids in EA.

Glucocorticoids update

Pubmed: n=145  Embase: n= 16  Cochrane: n=61

n=222

Excluded: n=219

Congress: n=1

4 new studies after 2009
Figure B: Literature search strategy for all RCTs reporting the efficacy of MTX monotherapy versus MTX in combination with other csDMARD

MTX combination vs monotherapy update

Pubmed: n=300
Embase: n=31
Cochrane: n=167

n=498

Excluded on the basis of the title and abstract: n=494
- Duplicates: n=165
- Not RA: n=23
- Not synthetic DMARDs combination: n=73
- Biologics: n=136
- Not RCT: n=20
- Not efficacy: n=58
- Not appropriate control group: n=11
- Phase 2 study: n=2
- Same study: n=3
- Not in English: n=1
- Not in humans: n=1
- Not appropriate outcome: n=1

n=4

Hand-search: n=1

Publications excluded after obtaining the full text: n=3
- Not RCT: n=2
- Not appropriate outcome: n=1

n=2 new studies
Figure C: Literature search strategy for all RCTs reporting the efficacy of tofacitinib

Tofacitinib

<table>
<thead>
<tr>
<th>Database</th>
<th>n</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pubmed</td>
<td>12</td>
</tr>
<tr>
<td>Embase</td>
<td>9</td>
</tr>
<tr>
<td>Cochrane</td>
<td>6</td>
</tr>
</tbody>
</table>

n=27

Excluded on the basis of the title and abstract: n=17
- Duplicates: n=15
- Not efficacy: n=2

n=10

Publications excluded after obtaining the full text: n=2
- Not efficacy: n=1
- Not RCT: n=1

n=33 presentations / publications
10 studies
## The efficacy of tofacitinib 5 mg BID versus placebo at 24 weeks

<table>
<thead>
<tr>
<th>Outcome</th>
<th>N Studies</th>
<th>N Patients</th>
<th>Statistical Method</th>
<th>Effect Estimate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain SRM</td>
<td>2</td>
<td>355</td>
<td>Std. Mean Difference (IV, Fixed, 95% CI)</td>
<td>0.45 [0.21, 0.69]</td>
</tr>
<tr>
<td>SJC SRM</td>
<td>2</td>
<td>355</td>
<td>Std. Mean Difference (IV, Random, 95% CI)</td>
<td>0.28 [-0.23, 0.78]</td>
</tr>
<tr>
<td>TJC SRM</td>
<td>2</td>
<td>355</td>
<td>Std. Mean Difference (IV, Fixed, 95% CI)</td>
<td>0.28 [0.04, 0.51]</td>
</tr>
<tr>
<td>Patient Global assessment SRM</td>
<td>2</td>
<td>355</td>
<td>Std. Mean Difference (IV, Random, 95% CI)</td>
<td>0.44 [0.03, 0.84]</td>
</tr>
<tr>
<td>Physician Global assessment SRM</td>
<td>2</td>
<td>354</td>
<td>Std. Mean Difference (IV, Fixed, 95% CI)</td>
<td>0.53 [0.29, 0.77]</td>
</tr>
<tr>
<td>HAQ SRM</td>
<td>3</td>
<td>573</td>
<td>Std. Mean Difference (IV, Fixed, 95% CI)</td>
<td>0.55 [0.36, 0.75]</td>
</tr>
<tr>
<td>DAS28-ESR SRM</td>
<td>2</td>
<td>484</td>
<td>Std. Mean Difference (IV, Fixed, 95% CI)</td>
<td>0.30 [0.06, 0.53]</td>
</tr>
<tr>
<td>ACR 20</td>
<td>5</td>
<td>1628</td>
<td>Odds Ratio (M-H, Fixed, 95% CI)</td>
<td>2.44 [1.97, 3.02]</td>
</tr>
<tr>
<td>ACR 70</td>
<td>3</td>
<td>845</td>
<td>Odds Ratio (M-H, Fixed, 95% CI)</td>
<td>2.87 [1.72, 4.80]</td>
</tr>
<tr>
<td>CRP SRM</td>
<td>2</td>
<td>354</td>
<td>Std. Mean Difference (IV, Fixed, 95% CI)</td>
<td>0.63 [0.39, 0.87]</td>
</tr>
</tbody>
</table>

## The efficacy of tofacitinib 10 mg BID versus placebo at 24 weeks

<table>
<thead>
<tr>
<th>Outcome</th>
<th>N Studies</th>
<th>N Patients</th>
<th>Statistical Method</th>
<th>Effect Estimate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain SRM</td>
<td>2</td>
<td>394</td>
<td>Std. Mean Difference (IV, Random, 95% CI)</td>
<td>0.49 [0.06, 0.92]</td>
</tr>
<tr>
<td>SJC SRM</td>
<td>2</td>
<td>395</td>
<td>Std. Mean Difference (IV, Random, 95% CI)</td>
<td>0.34 [-0.23, 0.91]</td>
</tr>
<tr>
<td>TJC SRM</td>
<td>2</td>
<td>395</td>
<td>Std. Mean Difference (IV, Fixed, 95% CI)</td>
<td>0.42 [0.19, 0.65]</td>
</tr>
<tr>
<td>Patient Global assessment SRM</td>
<td>2</td>
<td>394</td>
<td>Std. Mean Difference (IV, Random, 95% CI)</td>
<td>0.60 [0.37, 0.84]</td>
</tr>
<tr>
<td>Physician Global assessment SRM</td>
<td>2</td>
<td>394</td>
<td>Std. Mean Difference (IV, Random, 95% CI)</td>
<td>0.58 [-0.02, 1.18]</td>
</tr>
<tr>
<td>HAQ SRM</td>
<td>3</td>
<td>621</td>
<td>Std. Mean Difference (IV, Random, 95% CI)</td>
<td>0.59 [0.12, 1.06]</td>
</tr>
<tr>
<td>DAS28-ESR SRM</td>
<td>2</td>
<td>486</td>
<td>Std. Mean Difference (IV, Fixed, 95% CI)</td>
<td>0.52 [0.28, 0.75]</td>
</tr>
<tr>
<td>ACR20</td>
<td>5</td>
<td>1639</td>
<td>Odds Ratio (M-H, Random, 95% CI)</td>
<td>3.17 [2.11, 4.76]</td>
</tr>
<tr>
<td>ACR 70</td>
<td>2</td>
<td>742</td>
<td>Odds Ratio (M-H, Random, 95% CI)</td>
<td>3.08 [0.86, 11.03]</td>
</tr>
<tr>
<td>CRP SRM</td>
<td>2</td>
<td>395</td>
<td>Std. Mean Difference (IV, Random, 95% CI)</td>
<td>0.68 [-0.00, 1.36]</td>
</tr>
</tbody>
</table>

SJC: swollen joint count  
SRM: standardised response mean  
IV: inverse of variance  
MH: Mantel- Haenszel